Published 09/27/2024 3:06:49 p.m.

DARZALEX® (daratumumab)-based maintenance regimens show clinically meaningful deep and durable responses in transplant-eligible patients with newly diagnosed multiple myeloma

Summary by stocktitan.net

Discover how Johnson & Johnson's DARZALEX® therapies significantly improve multiple myeloma treatment outcomes. New data reveals increased efficacy and longer progression-free survival across patient populations.

0 Articles

All

Left

Center

Right

pipelinereview

TALVEY®▼ (talquetamab) and DARZALEX® (daratumumab) subcutaneous (SC) formulation-based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma - Pipelinereview

Updated data show 100 percent overall response rate, with 56 percent of patients achieving complete response or better with weekly dosing, supporting the combinability of the GPRC5D bispecific antibody1 Safety profile, including infection rates, is similar to talquetamab and daratumumab SC monotherapies1 BEERSE, Belgium I September 27, 2024 I Janssen-Cilag International NV, a Johnson & Johnson company, announced today updated results from the …

09/27/2024 3:06:49 p.m.

Read Full Article

stocktitan.net

DARZALEX® (daratumumab)-based maintenance regimens show clinically meaningful deep and durable responses in transplant-eligible patients with newly diagnosed multiple myeloma

09/27/2024 5:05:00 p.m.

Read Full Article

Pharmacy Times

Talquetamab-Daratumumab-Pomalidomide Combination Led to Durable Response in Patients With Relapsed/Refractory Multiple Myeloma

Promising depth of response and consistent safety profile support the use of talquetamab as a combination agent.

09/27/2024 6:49:22 p.m.

Read Full Article

cancernetwork.com

Talquetamab-Based Triplet Elicits Deep Responses in R/R Myeloma

Talquetamab plus daratumumab yields improved patient outcomes in patients with relapsed/refractory multiple myeloma.

09/27/2024 6:21:00 p.m.

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources0

Leaning Left0Leaning Right0Center0Last Updated09/28/2024 12:00:16 a.m.Bias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

DARZALEX® (daratumumab)-based maintenance regimens show clinically meaningful deep and durable responses in transplant-eligible patients with newly diagnosed multiple myeloma

0 Articles

0 Articles

TALVEY®▼ (talquetamab) and DARZALEX® (daratumumab) subcutaneous (SC) formulation-based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma - Pipelinereview

TALVEY®▼ (talquetamab) and DARZALEX® (daratumumab) subcutaneous (SC) formulation-based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma - Pipelinereview

DARZALEX® (daratumumab)-based maintenance regimens show clinically meaningful deep and durable responses in transplant-eligible patients with newly diagnosed multiple myeloma

DARZALEX® (daratumumab)-based maintenance regimens show clinically meaningful deep and durable responses in transplant-eligible patients with newly diagnosed multiple myeloma

Talquetamab-Daratumumab-Pomalidomide Combination Led to Durable Response in Patients With Relapsed/Refractory Multiple Myeloma

Talquetamab-Daratumumab-Pomalidomide Combination Led to Durable Response in Patients With Relapsed/Refractory Multiple Myeloma

Talquetamab-Based Triplet Elicits Deep Responses in R/R Myeloma

Talquetamab-Based Triplet Elicits Deep Responses in R/R Myeloma

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics